Cyramza ® (ramucirumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Cyramza Summary of Product Characteristics (SmPC)

Cyramza® (ramucirumab): Pregnancy and Lactation

Based on its mechanism of action, ramucirumab may cause foetal harm. It is recommended to avoid pregnancy and discontinue nursing while taking ramucirumab.

Pregnancy Risk Summary

No animal studies have been specifically conducted to evaluate the effect of ramucirumab on female reproduction and fetal development, and there are no studies in pregnant women1

Based on ramucirumab’s mechanism of action, it is likely that ramucirumab will inhibit angiogenesis and may potentially result in adverse effects during pregnancy and postnatal development.1

Avoid the use of ramucirumab in pregnant women, and only use if the potential benefit to the mother justifies the potential risk to the fetus. Counsel women of childbearing potential or women who become pregnant during treatment of the potential risks of ramucirumab to the fetus and for maintaining pregnancy.1

Based on the half-life of ramucirumab, advise females of reproductive potential to avoid getting pregnant while receiving ramucirumab and for at least 3 months after the last dose of ramucirumab.1

Animal Data

Animal models link

  • angiogenesis

  • VEGF, and

  • VEGFR-2

to critical aspects of

  • female reproduction

  • embryofetal development, and

  • postnatal development.2

Lactation Risk Summary

No studies have been conducted to assess ramucirumab’s impact on

  • milk production

  • its presence in breast milk, or

  • its effects on the breast-fed child.1

It is not known whether ramucirumab is secreted in human milk. Human immunoglobulin G is excreted in human milk and due to potential risks to the nursing infant, it is recommended to discontinue nursing or discontinue ramucirumab.1


1. Cyramza [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.


VEGF = vascular endothelial growth factor

VEGFR-2 = vascular endothelial growth factor receptor 2

Date of Last Review: March 20, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request